Título não disponível

Por Horning, Sandra
Publicado em 2006

Allied in Achieving the Best-Quality Cancer Care

Por Horning, Sandra
Publicado em 2006

Hodgkin lymphoma a comprehensive update on diagnostics and clinics /

Por Engert, Andreas., Horning, Sandra J.
Publicado em 2011

Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma

Por Weng, Wen-Kai, Negrin, Robert S., Lavori, Philip, Horning, Sandra J.
Publicado em 2010

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience

Por Chen, Andy I., McMillan, Alex, Negrin, Robert S., Horning, Sandra J., Laport, Ginna G.
Publicado em 2008

Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin’s Disease

Por Kohrt, Holbrook, Johannsen, Alexandre, Hoppe, Richard, Horning, Sandra J., Rosenberg, Saul A., Advani, Ranjana, Lee, Peter P.
Publicado no Oncol Res (2009)

Stage I-IIA Non-Bulky Hodgkin Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience

Por Advani, Ranjana H., Hoppe, Richard T, Maeda, Lauren S., Baer, David M., Mason, Joseph, Rosenberg, Saul A, Horning, Sandra J
Publicado em 2010

Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials

Por Koontz, Michael Zach, Horning, Sandra J., Balise, Raymond, Greenberg, Peter L., Rosenberg, Saul A., Hoppe, Richard T., Advani, Ranjana H.
Publicado em 2013

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

Por Advani, Ranjana H., Hong, Fangxin, Horning, Sandra J., Kahl, Brad S., Manola, Judith, Swinnen, Lode J., Habermann, Thomas M., Ganjoo, Kristen
Publicado em 2011

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

Por Horning, Sandra J., Juweid, Malik E., Schöder, Heiko, Wiseman, Gregory, McMillan, Alex, Swinnen, Lode J., Advani, Ranjana, Gascoyne, Randy, Quon, Andrew
Publicado em 2010

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

Por Tseng, Diane, Rachakonda, Leelanand P, Su, Zheng, Advani, Ranjana, Horning, Sandra, Hoppe, Richard T, Quon, Andrew, Graves, Edward E, Loo, Billy W, Tran, Phuoc T
Publicado em 2012

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Por Greenwald, Daniel R, Li, Hailun, Luger, Selina M, Go, Ronald S, King, David, Patel, Taral, Gascoyne, Randy D, Kolesar, Jill, Kahl, Brad S, Horning, Sandra
Publicado em 2013

Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

Por Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
Publicado em 2013

A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402

Por Witzig, Thomas E., Hong, Fangxin, Micallef, Ivana N., Gascoyne, Randy D., Dogan, Ahmet, Wagner, Henry, Kahl, Brad S., Advani, Ranjana H., Horning, Sandra J.
Publicado no Br J Haematol (2015)

Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma

Por Kenkre, Vaishalee P., Hong, Fangxin, Cerhan, James R., Lewis, Marcia, Sullivan, Leslie, Williams, Michael E., Gascoyne, Randy D., Horning, Sandra J., Kahl, Brad S.
Publicado no Clin Cancer Res (2015)

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG...

Por Hochster, Howard, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Ryan, Theresa, Zhang, Lijun, Colocci, Natalia, Frankel, Stanley, Horning, Sandra J.
Publicado em 2009

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell...

Por Smith, Mitchell R., Li, Hailun, Gordon, Leo, Gascoyne, Randy D., Paietta, Elisabeth, Forero-Torres, Andres, Kahl, Brad S., Advani, Ranjana, Hong, Fangxin, Horning, Sandra J.
Publicado em 2012

Developing Standards for Breakthrough Therapy Designation in Oncology

Por Horning, Sandra J., Haber, Daniel A., Selig, Wendy K.D., Ivy, S. Percy, Roberts, Samantha A., Allen, Jeff D., Sigal, Ellen V., Sawyers, Charles L.
Publicado em 2013

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Por Chang, Julie E., Li, Hailun, Smith, Mitchell R., Gascoyne, Randy D., Paietta, Elisabeth M., Yang, David T., Advani, Ranjana H., Horning, Sandra J., Kahl, Brad S.
Publicado em 2014

Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)

Por Swinnen, Lode J., Li, Hailun, Quon, Andrew, Gascoyne, Randy, Hong, Fangxin, Ranheim, Erik A., Habermann, Thomas M., Kahl, Brad S., Horning, Sandra J., Advani, Ranjana H.
Publicado no Br J Haematol (2015)